Alteration in innate immune cues assessed by analyzing peripheral blood immune system in post-covid patients

Russian Journal of Infection and Immunity, Journal Year: 2023, Volume and Issue: 13(5), P. 864 - 872

Published: Oct. 20, 2023

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to global morbidity and mortality. Some patients fully recover from COVID-19, whereas around 45% subjects suffer various persistent symptoms (fatigue, cognitive impairment, impaired thermoregulation, skin diseases, etc.) for at least four months after infection regardless of disease severity. Such post-infection effects are known as long-COVID, post-acute or post-COVID state. is accompanied damage innate immune system. Considering role natural killer cells activation complement system in well regulatory properties related CD46 its potential involvement cell virus entry, we found necessary study parameters associated with impairment these cues on leukocyte subpopulations patients. We studied 92 parameters, including: pan-leukocyte markers gated lymphocytes, phenotyping T cells, T-helper inducers, cytotoxic T-lymphocytes, NK- TNK-cells, T-regulatory cells/suppressors, B-lymphocytes, including B-memory activated helpers, early late lymphocyte markers. Levels total IgM, IgG, IgA, specific IgG coronavirus C1-inhibitor, C3a, C5a components were measured enzyme immunoassay using Multiscan FC Thermoscientific analyzer (China) Vector Best reagent kits (Russia). A complete blood count was conducted 25 parameters: leukocyte, erythrocyte, platelet hematopoietic lineages quantitative qualitative composition lineages. Our results showed that some patients, six suffering there a decrease level NK (48%) CD46+pan-leukocyte marker (64.5%). levels increased T- altered erythroid In reduced expression both their significantly reduced. data also suggest might be potentially involved development Thus, 50–65% who have experienced infection, persists being obtained indicate need immunocorrective therapy such

Language: Английский

---

Is there a role for growth hormone replacement in adults to control acute and post-acute COVID-19?

Best Practice & Research Clinical Endocrinology & Metabolism, Journal Year: 2023, Volume and Issue: 37(6), P. 101842 - 101842

Published: Nov. 19, 2023

Language: Английский

---

New‐onset primary Sjögren's syndrome following exposure to severe acute respiratory syndrome coronavirus 2: A retrospective cohort study

Rheumatology & autoimmunity, Journal Year: 2024, Volume and Issue: 4(1), P. 37 - 46

Published: March 1, 2024

Abstract Background Understanding the clinical implications of autoimmune manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is essential to reduce its consequences. This study was aimed at determining activities new‐onset primary Sjögren (pSS) since emergence SARS‐CoV‐2. Methods retrospective cohort included data from 471 participants dry mouths and eyes who had been attending Nanjing Drum Tower Hospital December 2019. By April 2023, patients diagnosed pSS were sequentially assigned vaccinated group ( n = 24) or infected based on exposure 20). Patients within 3 months vaccination against SARS‐CoV‐2 a group, those then developed follow up after direct group. The controls comprised age‐ sex‐matched not exposed before 2019 21). We compared among three groups. Results more fever, malaise, splenomegaly, weight loss diagnosis higher European Alliance Associations for Rheumatology Sjögren's disease activity index time onset than other two Vaccinated frequency anti‐nuclear antibody (ANA) titers > 1:320 12; 50%) anti‐phospholipid antibodies (aPL) 7; 29%) controls. anti‐Ro/SSA (13, 65%), ANA 16; 80%), aPLs 5; 25%) all significantly in infection Higher doses glucocorticoids, cyclosporin A, tacrolimus administered control groups p < 0.05, all). Conclusions history might have active disease. Further strengthening assessment people clear SARS‐CoV monitoring potential populations screening should be overlooked.

Language: Английский

---

International Roadshow: New Advances in Endocrinology and Metabolic Diseases

Hormone and Metabolic Research, Journal Year: 2024, Volume and Issue: 56(04), P. 259 - 260

Published: April 1, 2024

Dear Readers, Currently, there is a myriad of new developments in the field endocrinology. In particular, significant strides have been made development poly-agonists for treatment type 2 diabetes and obesity 1 2. Poly-agonists represent novel therapeutic approach by combining multiple actions within single molecule, targeting receptors simultaneously to achieve enhanced efficacy. These innovative compounds aim address complex interplay hormonal pathways involved glucose regulation metabolism, offering potential breakthroughs management obesity.

Language: Английский

---

Marine Sponge-Derived Secondary Metabolites Modulate SARS-CoV-2 Entry Mechanisms

Hormone and Metabolic Research, Journal Year: 2023, Volume and Issue: 56(04), P. 308 - 317

Published: Oct. 4, 2023

Abstract The emergence of SARS-CoV 2 caused the COVID-19 pandemic, resulting in numerous global infections and deaths. In particular, people with metabolic diseases display an increased risk severe COVID 19 a fatal outcome. Treatment options for cases are limited, appearance new virus variants complicates development novel therapies. To better manage viral like 19, therapeutic approaches needed. Marine sponges offer natural renewable source unique bioactive agents. These produce secondary metabolites various effects, including anti-viral, anti-inflammatory, anti-tumorigenic properties. current study, we investigated effect five different marine sponge-derived (four bromotyrosines one sesquiterpenoid hydroquinone). Two these, Avarol Acetyl-dibromoverongiaquinol reduced expression ACE2, main receptor 2, alternative NRP1. Moreover, these substances derived from demonstrated ability to diminish titer 2-infected cells, especially concerning Omicron lineage. However, reduction was not substantial enough expect significant impact on infected humans. Consequently, likely be effective treat as stand-alone therapy.

Language: Английский

---

КОРОНАВИРУСНАЯ ИНФЕКЦИЯ И COVID-19 У ДЕТЕЙ. ЧАСТЬ 1. ЭПИДЕМИОЛОГИЯ, ЭТИОЛОГИЯ, ПАТОГЕНЕЗ

Children s medicine of the North-West, Journal Year: 2024, Volume and Issue: 12(4), P. 21 - 38

Published: Dec. 3, 2024

В лекции представлены данные об эпидемиологии коронавирусов как возбудителей сезонных респираторных ви русных инфекций у детей, а также о вирусе SARS-CoV-2, который вызвал пандемию COVID-19. Приведена классификация, морфология и структура коронавирусов. Показаны источник, пути передачи возбудителя при новой коронавирусной инфекции, уделено внимание роли COVID-19 инфек ции, связанной с оказанием медицинской помощи. Описаны особенности строения его антигенные детерминанты, обеспечивающие проникновение вируса в клетки-мишени, основные альтернативные механизмы проникновения клетки. Указаны которые высоко экспрессируют рецепторы входа для SARS-CoV-2. Подробно представлен патогенез патоморфологические изменения органах тканях детей. The lecture presents data on the epidemiology of coronaviruses as causative agents seasonal respiratory viral infections in children, well SARS-CoV-2 virus, which caused pandemic. classification, morphology and structure are given. source transmission routes pathogen a new coronavirus infection shown, attention is paid to role an associated with healthcare. structural features its antigenic determinants that ensure penetration virus into target cells, main alternative mechanisms cells described. Target highly express entry receptors for indicated. pathogenesis infection, pathomorphological changes organs tissues presented detail

Language: Русский

---